BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schizas D, Mastoraki A, Routsi E, Papapanou M, Tsapralis D, Vassiliu P, Toutouzas K, Felekouras E. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int 2020;19:515-23. [PMID: 32753331 DOI: 10.1016/j.hbpd.2020.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Li S, Feng Y, Zhang J, Peng Y, Wang X, Wang H. The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery. CMAR 2022;Volume 14:1795-806. [DOI: 10.2147/cmar.s361462] [Reference Citation Analysis]
2 Wu Y, Liu H, Zeng J, Chen Y, Fang G, Zhang J, Zhou W, Zeng Y, Liu J. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study. World J Surg Onc 2022;20. [DOI: 10.1186/s12957-022-02536-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wang J, Li Z, Liao Y, Li J, Dong H, Peng H, Xu W, Fan Z, Gao F, Liu C, Liu D, Zhang Y. Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study. Front Oncol 2021;11:686972. [PMID: 34336671 DOI: 10.3389/fonc.2021.686972] [Reference Citation Analysis]
4 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
5 Hou GM, Jiang C, Du JP, Yuan KF. Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery. Cancer Med 2021. [PMID: 34866356 DOI: 10.1002/cam4.4448] [Reference Citation Analysis]
6 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Huo X, Zhou H, Li T, Xu Z. MicroRNA-4325 Suppresses Cell Progression in Hepatocellular Carcinoma via GATA-Binding Protein 6. BioMed Research International 2021;2021:1-9. [DOI: 10.1155/2021/6616982] [Reference Citation Analysis]
8 Chen X, Lu Y, Shi X, Chen X, Rong D, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma. J Oncol 2021;2021:3002480. [PMID: 34925507 DOI: 10.1155/2021/3002480] [Reference Citation Analysis]
9 Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen X, Sun S, Lu Y, Shi X, Wang Z, Chen X, Han G, Zhao J, Gao Y, Wang X. Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis. Ann Transl Med 2022;10:434. [PMID: 35571416 DOI: 10.21037/atm-21-5391] [Reference Citation Analysis]
11 Wang Y, Zhu GQ, Zhou CW, Li N, Yang C, Zeng MS. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors. Eur Radiol 2022. [PMID: 35316365 DOI: 10.1007/s00330-022-08691-w] [Reference Citation Analysis]
12 Guo HL, Lu XZ, Hu HT, Ruan SM, Zheng X, Xie XY, Lu MD, Kuang M, Shen SL, Chen LD, Wang W. Contrast-Enhanced Ultrasound-Based Nomogram: A Potential Predictor of Individually Postoperative Early Recurrence for Patients With Combined Hepatocellular-Cholangiocarcinoma. J Ultrasound Med 2021. [PMID: 34751450 DOI: 10.1002/jum.15869] [Reference Citation Analysis]
13 Hou GM, Liu HL, Wu H, Zeng Y. Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. Ann Surg Oncol 2021. [PMID: 33900502 DOI: 10.1245/s10434-021-09949-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Reference Citation Analysis]
15 Laohawetwanit T, Lerttanatum N, Wanpiyarat N, Manasilp N, Chaiparnich S. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology. Ann Diagn Pathol 2021;53:151770. [PMID: 34147845 DOI: 10.1016/j.anndiagpath.2021.151770] [Reference Citation Analysis]
16 Jia Y, Xing Y, Yang M. Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT. J Oncol 2021;2021:9120265. [PMID: 34434234 DOI: 10.1155/2021/9120265] [Reference Citation Analysis]
17 Chen Y, Lu Q, Zhang W, Cao J, Dong Y, Wang W. Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Nomogram Based on Ultrasonographic Features and Clinical Indicators. Front Oncol 2022;12:757774. [PMID: 35242699 DOI: 10.3389/fonc.2022.757774] [Reference Citation Analysis]